drugset
drugset / Trial / NCT07132008

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

NCT07132008 ↗

Phase 3 Not yet recruiting 94 enrolled First Affiliated Hospital of Guangxi Medical University The First Affiliated Hospital of University of South China · collabThe First Affiliated Hospital of Xiamen University · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Building on earlier exploratory work, this study further designs a multi-institutional, prospective, randomized clinical trial to evaluate the efficacy and safety of the combination therapy of the immune checkpoint inhibitor Tislelizumab with CAPOX for neoadjuvant treatment in high-risk locally advanced MSS-type colorectal cancer, as well as its impact on patient outcomes. This study aims to provide new evidence for the clinical practice of treating MSS-type colorectal cancer.

Timeline

Start
2025-10-01
Primary completion
2027-09-30
Completion
2030-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg —
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Oxaliplatin Small molecule 130 mg/m2 —

Indications

colonic neoplasm